

The ONLY Selective Targeted Therapy for Advanced Systemic Mastocytosis

Designed for potent inhibition of KIT D816V¹

NCCN
RECOMMENDED

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) recommend avapritinib (AYVAKIT) (if platelets $\geq 50 \times 10^9/L$) as an NCCN Category 2A, preferred first-line treatment option for advanced systemic mastocytosis (SM), including aggressive SM (ASM), SM with an associated hematologic neoplasm (SM-AHN) (when the SM component requires prioritization over the AHN component), and mast cell leukemia (MCL).²

NCCN=National Comprehensive Cancer Network.

INDICATION

AYVAKIT[®] (avapritinib) is indicated for the treatment of adult patients with advanced SM (AdvSM) including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of $< 50 \times 10^9/L$.

SELECT SAFETY INFORMATION

Intracranial Hemorrhage—Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in $< 1\%$ of patients. Overall, ICH (e.g., subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT in clinical trials. In AdvSM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts $\geq 50 \times 10^9/L$ prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts.


Please see Important Safety Information on pages 16-17 and the full [Prescribing Information](#) for AYVAKIT.

Advanced SM can lead to significant disease burden and shortened overall survival³⁻⁵

Advanced SM is a clonal mast cell neoplasm **causing significant symptom burden and impact to quality of life.**^{3,4}

Patients may exhibit debilitating mast cell mediator symptoms, such as rash and life-threatening anaphylaxis.⁴

Additionally, patients with Advanced SM can experience organ damage, including ascites, osteolytic lesions, pleural effusion, liver dysfunction, weight loss, cytopenias, and hypersplenism.^{4,6-8}




Advanced SM may be missed in patients with other myeloid neoplasms.¹⁰

The median time from symptom onset to diagnosis for patients with Advanced SM is 3 years.^{4*}

*Based on a survey in patients with Advanced SM (n=13).

Advanced SM is driven by KIT D816V in ~95% of cases^{6,11,12}

The KIT D816V mutation constitutively activates downstream pathways regulating cellular functions including proliferation and survival of abnormal mast cells.^{13,14}



Historically, patients with Advanced SM had **no treatment options that selectively targeted the underlying mutation.**^{8,15}

KIT=KIT proto-oncogene, receptor tyrosine kinase.

WHO Diagnostic Criteria^{16*}

DIAGNOSIS OF SM REQUIRES THE PRESENCE OF 1 MAJOR CRITERION AND ≥1 MINOR CRITERION, OR ≥3 MINOR CRITERIA

Major criterion

- Multifocal dense infiltrates of mast cells (≥15 mast cells in aggregates) detected in sections of bone marrow and/or other extracutaneous organ(s)

Minor criteria

- Atypical mast cell morphology, including spindle shape or immature morphology, present in >25% of all mast cells on bone marrow smears or in other extracutaneous organ(s)[†]
- Mast cells aberrantly express one or more of the following antigens: CD2, CD25, CD30
- KIT D816V mutation or other activating KIT mutation[‡] detected in peripheral blood, bone marrow, or other extracutaneous organ(s)
- Baseline serum tryptase concentration of >20 ng/mL in the absence of an associated myeloid neoplasm; in the case of a known HαT, the tryptase level could be adjusted[§]

FOR AN ADVANCED SM DIAGNOSIS, CRITERIA FOR 1 OF THE ADVANCED SM SUBTYPES MUST BE MET

ASM

- SM criteria fulfilled
- ≥1 C-finding:
 - » ≥1 cytopenia(s) (ANC <1 x 10⁹/L, hemoglobin <10 g/dL, or platelets <1.0 x 10⁹/L)
 - » Hepatopathy: ascites and elevated liver enzymes^{||} ± hepatomegaly or cirrhotic liver ± portal hypertension
 - » Spleen: palpable splenomegaly with hypersplenism ± weight loss ± hypoalbuminemia
 - » Gastrointestinal tract: malabsorption with hypoalbuminemia ± weight loss
 - » Bone: large-sized osteolysis (≥20 mm) ± pathologic fracture ± bone pain

SM-AHN

- SM criteria fulfilled
- Meets criteria for AHN as a distinct entity per the WHO classification

MCL

- SM criteria fulfilled
- ≥20% mast cells in bone marrow aspirate smears
- In classic cases, mast cells account for ≥10% of peripheral blood white cells. In aleukemic cases, mast cells account for <10% of peripheral blood white cells
- In acute cases, C-findings are detectable, while chronic cases have no detectable C-findings

Subtyping may be complex and require expert consultation.

*According to the proposed changes for the WHO 5th edition diagnostic criteria.

[†]Well-differentiated round cell morphology may be seen in a small subset of cases; mast cells in such cases are usually positive for CD30 and negative for CD2 and CD25.

[‡]Any type of KIT mutation counts as a minor SM criterion when published solid evidence for its transforming behavior is available (an overview of potentially activating KIT mutations is provided in the supplementary material of Valent et al [2021]).

[§]A possible mode for adjustment has been proposed by Valent et al [2021]: the basal tryptase level may be divided by 1 plus the number of extra copies of the α-tryptase gene. For example, if the tryptase level is 30 ng/mL and 2 extra copies of the α-tryptase gene are found in a patient with HαT, the HαT-corrected tryptase level is 10 ng/mL (30/3=10), thereby not meeting the level of a minor SM criterion.

^{||}Alkaline phosphatase levels are typically elevated in patients with Advanced SM and SM-induced liver damage. In some of these patients, only elevated liver enzymes are found, without (clinically relevant) ascites.

AHN=associated hematological neoplasm; ANC=absolute neutrophil count; CD=cluster of differentiation; HαT=hereditary alpha-tryptasemia; WHO=World Health Organization.

A thorough diagnostic workup is critical for ensuring an accurate diagnosis^{7,13}

IN A RETROSPECTIVE ANALYSIS OF 140 PATIENTS WITH ADVANCED SM FROM A GERMAN ECNM CENTER^{10*}:



Misdiagnoses were identified in ~36% (51/140) of patients.

Advanced SM was overlooked in 20% (28/140) of patients initially diagnosed with myeloid neoplasms.

COMPLETING A FULL DIAGNOSTIC WORKUP^{7,13}

Accurately diagnosing a patient with Advanced SM requires a full diagnostic workup, which can include:



- Bone marrow biopsy (top markers CD117 and CD25)
- Mast cell immunophenotyping
- Serum tryptase test
- KIT D816V mutation testing

Incidental KIT mutation findings should prompt full diagnostic workup for Advanced SM¹⁷

UP TO 70% OF PATIENTS WITH ADVANCED SM HAVE AN AHN¹⁸



KIT MUTATION ON MYELOID NGS PANEL

INCIDENTAL KIT FINDING SHOULD TRIGGER A FULL DIAGNOSTIC WORKUP¹⁷

- Myeloid mutation panels alone are not recommended for the detection of KIT D816V. NGS assays can exhibit low sensitivity, and higher sensitivity assays should always be performed^{3,19,20}
- Continue to monitor for signs and symptoms and perform mutational testing with a high-sensitivity KIT D816V assay if Advanced SM is suspected^{3,19}

*Analysis included 140 patients who were referred, diagnosed, and treated at the German ECNM center for mast cell disorders between January 2009 and December 2018; classification was based on the WHO criteria.

AML=acute myeloid leukemia; CEL=chronic eosinophilic leukemia; CMML=chronic myelomonocytic leukemia; ECNM=European Competence Network on Mastocytosis; MDS=myelodysplastic syndrome; MDS/MPN=myelodysplastic syndrome/myeloproliferative neoplasm; MPN=myeloproliferative neoplasm; NGS=next-generation sequencing.


Target the underlying mutation >

The ONLY treatment to selectively target the underlying mutation¹

AVAPRITINIB IS A TYROSINE KINASE INHIBITOR DESIGNED FOR POTENT AND SELECTIVE INHIBITION OF KIT D816V



AYVAKIT potently and selectively inhibits autophosphorylation of the KIT receptor produced by the KIT D816V mutation, with an IC₅₀ of 4 nanomoles in selective cellular assays.



KIT D816V testing is not required for AYVAKIT treatment

SELECT SAFETY INFORMATION

Intracranial Hemorrhage (cont'd)—Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH. Permanently discontinue AYVAKIT if ICH of any grade occurs.

A platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in AdvSM patients with platelet counts <50 x 10⁹/L. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of <50 x 10⁹/L by treatment interruption or dose reduction.

Please see Important Safety Information on pages 16-17 and the full [Prescribing Information](#) for AYVAKIT.

The efficacy and safety of AYVAKIT were evaluated in EXPLORER and PATHFINDER¹

MULTICENTER, SINGLE-ARM, OPEN-LABEL CLINICAL TRIALS FOR PATIENTS WITH ADVANCED SM



53 patients were evaluable for a response across the 2 trials, with median follow-up of 11.6 months (95% CI: 9.9 to 16.3 months).*

EXPLORER²¹

- Phase 1 dose-finding study to determine maximum tolerated dose
- Patients received a starting, once-daily dose of 30-400 mg

PATHFINDER²²

- Phase 2 study evaluating efficacy and safety
- Patients received a starting, once-daily dose of 200 mg

Efficacy was based on overall response rate (ORR) in 53 patients with Advanced SM dosed at up to 200 mg daily, per modified IWG-MRT-ECNM criteria as adjudicated by the central committee. In the subgroup of patients with MCL, the efficacy was based on CR.

Demographic Characteristics at Baseline (N=53)	
Median age	67 years (37-85)
Gender	58% male, 42% female
ECOG PS	0-1: 68%
	2-3: 32%
Ongoing corticosteroid use	40%
Presence of KIT D816V mutation	94% (as measured by ddPCR)
Prior antineoplastic therapy	66%
Prior midostaurin	47%
Advanced SM subtypes	ASM: 3.8% (n=2)
	SM-AHN: 75.5% (n=40)
	MCL: 20.7% (n=11)
Baseline platelet count ≥50 x 10 ⁹ /L	91%

*Response-evaluable patients: Confirmed diagnosis of Advanced SM per WHO criteria and deemed evaluable by modified IWG-MRT-ECNM criteria at baseline. Received at least 1 dose of AYVAKIT, had at least 2 postbaseline bone marrow assessments, and were on study for at least 24 weeks, or had an end-of-study visit.


CR=complete remission; ddPCR=droplet digital polymerase chain reaction; ECOG PS=Eastern Cooperative Oncology Group Performance Status; IWG-MRT-ECNM=International Working Group-Myeloproliferative Neoplasms Research and Treatment-European Competence Network on Mastocytosis.

See how efficacy was evaluated >

Efficacy tested by updated, clinically meaningful criteria^{7,23}

AYVAKIT IS THE FIRST THERAPY APPROVED BY THE FDA USING THE MODIFIED IWG CRITERIA TO EVALUATE EFFICACY FOR ADVANCED SM PATIENTS

The modified IWG criteria evaluate overall response rate (CR + PR) by:



*Organ damage may include:

- Nonhematologic
 - Ascites or pleural effusions
 - Liver function abnormalities
 - Marked symptomatic splenomegaly
 - Hypoalbuminemia
 - Weight loss
- Hematologic
 - Neutropenia
 - Anemia
 - Thrombocytopenia

†Serum tryptase must be <20 ng/mL if baseline was ≥40 ng/mL for CR or CRh.

CRh=complete remission with partial hematologic recovery; FDA=Food and Drug Administration; PR=partial remission.

SELECT SAFETY INFORMATION

Cognitive Effects—Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 33% of 995 patients overall in patients who received AYVAKIT in clinical trials including 28% of 148 AdvSM patients (3% were Grade ≥3). Depending on the severity and indication, withhold AYVAKIT and then resume at same dose or at a reduced dose upon improvement, or permanently discontinue.

Please see Important Safety Information on pages 16-17 and the full [Prescribing Information](#) for AYVAKIT.

SELECTIVE MODIFIED IWG-MRT-ECNM RESPONSE CRITERIA²⁴

CR*
Requires all 4 criteria and response duration must be ≥12 weeks:
No presence of compact neoplastic mast cell aggregates in the bone marrow or other biopsied extracutaneous organ
Serum tryptase level <20 ng/mL [†]
Peripheral blood count remission defined as ANC ≥1 × 10 ⁹ /L with normal differential, hemoglobin level ≥11 g/dL, and platelet count ≥100 × 10 ⁹ /L
Complete resolution of palpable hepatosplenomegaly and all biopsy-proven or suspected SM-related organ damage (C-findings) [‡]
CRh*
Requires all criteria for CR be met and response duration must be ≥12 weeks; however, patient may have residual cytopenias. The following minimum recovery of peripheral blood counts is required:
ANC >0.5 × 10 ⁹ /L with normal differential (absence of neoplastic mast cell and blasts <1%) and
Platelet count >50 × 10 ⁹ /L and
Hemoglobin level >8.0 g/dL
PR*
Requires all 3 of the following criteria and response duration must be ≥12 weeks, in the absence of CR/CRh and progressive disease (PD):
Reduction by ≥50% in neoplastic mast cells in the bone marrow [§] and/or other extracutaneous organ at biopsy demonstrating eligible SM-related organ damage
Reduction of serum tryptase level by ≥50% [†]
Resolution of 1 or more biopsy-proven or suspected SM-related organ damage (C-finding[s]) [‡]
Clinical improvement*
Response duration must be ≥12 weeks
Requires 1 or more of the nonhematologic and/or hematologic response criteria to be fulfilled in the absence of CR, CRh, PR, or PD

*Responses that are not maintained for a period of at least 12 weeks do not fulfill criteria for CR/CRh, PR, or CI; however, both maintained and unmaintained (<12 weeks duration) responses should be recorded in the electronic case report form each time they are observed to measure duration of response.

[†]Only valid as a response criterion if the pretreatment serum tryptase level is ≥40 ng/mL (ie, if pretreatment serum tryptase is <40 ng/mL, it will not be considered as a criterion in evaluation of response).

[‡]Biopsy of organ(s) in addition to the bone marrow to evaluate for SM-related organ damage may be considered.

[§]Only valid as a response criterion if the pretreatment bone marrow mast cells are ≥5% (ie, if pretreatment bone marrow mast cells are <5%, bone marrow mast cells will not be considered as a criterion in evaluation of response).

Proven efficacy and demonstrated duration of response¹

ORR across all evaluable Advanced SM patients (N=53)^a who were dosed up to 200 mg daily^{1,24}



[95% CI: 42%, 70%]*

● CR+CRh: 28% ● PR: 28% ● Clinical improvement: 15%

72% ORR was achieved with the addition of patients who had a clinical improvement^b

*ORR per modified IWG-MRT-ECNM is defined as patients who achieved a CR, CRh, or PR. Modified IWG criteria evaluated overall response rate by ≥12 weeks response duration, resolution of ≥1 findings of nonhematologic and hematologic organ damage (C-findings), and ≥50% reduction in mast cell burden and serum tryptase (must be <20 ng/mL if baseline was ≥40 ng/mL for CR/CRh).

^aMedian duration of follow-up was 11.6 months [95% CI: 9.9, 16.3].

^bClinical improvement is defined as having a response duration of ≥12 weeks and fulfillment of 1 or more of the nonhematologic and/or hematologic response criteria.⁷

Median DOR across all Advanced SM patients¹

38.3 MONTHS

[95% CI: 19, NE] driven primarily by SM-AHN patients

DOR=duration of response; NE=not estimable.

PATIENT TIME TO TREATMENT RESPONSE:

2.1 MONTHS

Median time to response (n=30)²⁴

9.2 MONTHS

Median time to CR and CRh (n=15)²⁴


SELECT SAFETY INFORMATION

Photosensitivity—AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment.

Please see Important Safety Information on pages 16-17 and the full [Prescribing Information](#) for AYVAKIT.

Proven efficacy across subtypes and regardless of prior antineoplastic therapy^{1,24}

EFFICACY ACROSS ADVANCED SM SUBTYPES¹



IN A PREPLANNED SUBGROUP ANALYSIS, AYVAKIT DEMONSTRATED EFFICACY REGARDLESS OF PRIOR ANTINEOPLASTIC THERAPY²⁴

In treatment-naive patients (n=18), **ORR was 72.2%** (95% CI: 46.5%, 90.3%)

In patients with prior antineoplastic therapy (including midostaurin) (n=35), **ORR was 48.6%** (95% CI: 31.4%, 66%)

SELECT SAFETY INFORMATION

Embryo-Fetal Toxicity—AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks following the final dose.

See adverse reactions from clinical trials >

AYVAKIT was generally well tolerated¹

THE MAJORITY OF ADVERSE REACTIONS WERE GRADE 1 OR 2

Adverse reactions (≥10%) for patients receiving 200 mg once-daily starting dose in EXPLORER and PATHFINDER (N=80)*

Adverse Reactions	All Grades, %	Grade ≥3, %
General		
Edema ^a	79	5
Fatigue/asthenia	23	4
Gastrointestinal		
Diarrhea	28	1
Nausea	24	1
Vomiting	18	3
Abdominal pain ^b	14	1
Constipation	11	0
Nervous system		
Headache	15	0
Cognitive effects ^c	14	1
Taste effects ^d	13	0
Dizziness	13	0
Musculoskeletal and connective tissue		
Arthralgia	10	1
Respiratory, thoracic, and mediastinal		
Epistaxis	11	0

Among patients receiving AYVAKIT, 70% were treated for 6 months or longer and 37% were exposed for greater than 1 year.

For patients receiving the recommended starting dose of 200 mg in clinical trials (N=80):

- **Serious adverse reactions were seen in 34% of patients**
- **Fatal adverse reactions occurred in 2.5% [2/80] of patients**
- **No specific adverse reaction leading to death was reported in more than 1 patient**
- **10% of patients permanently discontinued due to any adverse reaction**

*Per National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 and 5.0.

^aEdema includes face swelling, eyelid edema, orbital edema, periorbital edema, face edema, peripheral edema, edema, generalized edema, and peripheral swelling.

^bAbdominal pain includes abdominal pain, upper abdominal pain, and abdominal discomfort.

^cCognitive effects include memory impairment, cognitive disorder, confusional state, delirium, and disorientation.

^dTaste effects include dysgeusia.

SELECT SAFETY INFORMATION

Adverse Reactions—The most common adverse reactions (≥20%) were edema, diarrhea, nausea, and fatigue/asthenia.

Drug Interactions — Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors. If coadministration with a moderate CYP3A inhibitor cannot be avoided, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers. If contraception requires estrogen, limit ethinyl estradiol to ≤20 mcg unless a higher dose is necessary.

To report suspected adverse reactions, contact Blueprint Medicines Corporation at **1-888-258-7768** or the **FDA at 1-800-FDA-1088** or www.fda.gov/medwatch.

Please see Important Safety Information on pages 16-17 and the full [Prescribing Information](#) for AYVAKIT.

Lab abnormalities (≥10%) for patients receiving 200 mg once-daily starting dose in EXPLORER and PATHFINDER (N=80)¹

Laboratory Abnormality	All Grades, %	Grade ≥3, %
Hematology		
Decreased platelets		21
Decreased hemoglobin	55	23
Decreased neutrophils	54	25
Decreased lymphocytes	34	11
Increased activated partial thromboplastin time	14	1
Increased lymphocytes	10	0
Chemistry		
Decreased calcium	50	3
Increased bilirubin	41	3
Increased aspartate aminotransferase	38	1
Decreased potassium	26	4
Increased alkaline phosphatase	24	5
Increased creatinine	20	0
Increased alanine aminotransferase	18	1
Decreased sodium	18	1
Decreased albumin	15	1
Decreased magnesium	14	1
Increased potassium	11	0


Clinically relevant adverse reactions occurring in <10% of patients were:

Cardiac: cardiac failure (2.5%) and cardiac failure congestive (1.3%). Gastrointestinal: ascites (5%), gastrointestinal hemorrhage (1.3%), and large intestine perforation (1.3%). Hepatobiliary: cholelithiasis (1.3%). Infections and infestations: upper respiratory tract infection (6%), urinary tract infection (6%), and herpes zoster (2.5%). Vascular: flushing (3.8%), hypertension (3.8%), hypotension (3.8%), and hot flush (2.5%). Nervous: insomnia (6%). Musculoskeletal and connective tissue: pain in extremity (6%). Respiratory, thoracic, and mediastinal: dyspnea (9%) and cough (2.5%). Skin and subcutaneous tissue: rash (rash and rash maculo-papular) (8%), alopecia (9%), pruritus (8%), and hair color changes (6%). Metabolism and nutrition: decreased appetite (8%). Eye: lacrimation increased (9%). Laboratory abnormality: decreased phosphate (9%).


Starting AYVAKIT—dosing, cognitive effects, and platelet monitoring¹

THE RECOMMENDED DOSAGE OF AYVAKIT FOR ADVANCED SM IS 200 MG ORALLY ONCE DAILY¹

AYVAKIT should be taken¹:



One tablet orally



One time each day



On an empty stomach, at least 1 hour before or 2 hours after a meal

Treatment should continue until disease progression or unacceptable toxicity. Dose reductions as described in the AYVAKIT Prescribing Information may also be considered for adverse reactions as clinically appropriate. Do not initiate AYVAKIT in patients with platelet counts $<50 \times 10^9/L$.

IT WAS COMMON TO MODIFY AYVAKIT DOSAGE¹

Many patients in the EXPLORER and PATHFINDER trials had their dose reduced or interrupted due to adverse reactions.¹

Dose modifications for patients in clinical trials who started at 200 mg (N=80)¹:

- Dose interruption: **60%**
- Dose reduction: **68%** (median time to reduction: 6.9 weeks)
- Permanent discontinuation due to adverse reaction: **10%**

Adverse reactions requiring dosage interruption or dose reduction in $>2\%$ of patients who received AYVAKIT at 200 mg once daily¹:

- Thrombocytopenia
- Neutropenia
- Anemia
- Elevated blood alkaline phosphatase
- Cognitive disorder
- Peripheral edema
- Periorbital edema
- Fatigue
- Arthralgia

 Review the AYVAKIT **Prescribing Information** and download the **AYVAKIT Dosing and Patient Management Guide** at AYVAKITHCP.com/advsm for more detailed information on dose modifications.

SELECT SAFETY INFORMATION

Intracranial Hemorrhage—Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in $<1\%$ of patients. Overall, ICH (e.g., subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT in clinical trials. In AdvSM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts $\geq 50 \times 10^9/L$ prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts.

Please see **Important Safety Information** on pages 16-17 and the full [Prescribing Information](#) for AYVAKIT.

PLATELET MONITORING FOR ICH IS ESSENTIAL FOR TREATMENT WITH AYVAKIT¹

Platelet monitoring schedule

Time on therapy	Monitoring and treatment plan
Prior to initiation	Perform a platelet count. AYVAKIT is not recommended in Advanced SM patients with platelet counts $<50 \times 10^9/L$.
First 8 weeks	Perform platelet count every 2 weeks regardless of baseline platelet count.
After 8 weeks	Monitor platelet counts: <ul style="list-style-type: none"> • Every 2 weeks if values are $<75 \times 10^9/L$ (or more frequently as clinically indicated) • Every 4 weeks if values are $75-100 \times 10^9/L$ • As clinically indicated if values are $>100 \times 10^9/L$

Due to risk of ICH, dose interruption or reduction should be considered if platelet counts decrease below $50 \times 10^9/L$ during treatment. If platelet count $<50 \times 10^9/L$ occurs, interrupt AYVAKIT until platelet count is $\geq 50 \times 10^9/L$, then resume at reduced dose. If platelet counts do not recover above $50 \times 10^9/L$, consider platelet support.

Platelet monitoring must be performed prior to initiating therapy and throughout treatment with AYVAKIT.

Serious ICH may occur with AYVAKIT treatment. ICH occurred in 2.7% (2/75) of the patients with Advanced SM who had platelet counts of $\geq 50 \times 10^9/L$ at initiation of the recommended 200-mg dose and in 3.8% (3/80) of patients regardless of platelet counts. Fatal events of ICH have occurred in $<1\%$ of Advanced SM patients treated with any dose of AYVAKIT.

Thrombocytopenia was generally reversible by reducing or interrupting AYVAKIT. Dose interruptions and dose reductions for thrombocytopenia occurred in 20% and 22% of AYVAKIT-treated patients, respectively. Manage platelet counts of $<50 \times 10^9/L$ by treatment interruption or dose reduction of AYVAKIT.

Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia.

MONITOR PATIENTS FOR COGNITIVE EFFECTS DURING TREATMENT WITH AYVAKIT¹

Cognitive adverse reactions can occur in patients receiving AYVAKIT. For patients with Advanced SM started at the 200-mg recommended dose, cognitive effects occurred in 14% of 80 patients. Of the 148 patients with Advanced SM who received AYVAKIT at all doses, cognitive effects occurred in 28% of patients, with a median time to onset for the first cognitive adverse reaction of 13.3 weeks (range: 1 day to 1.8 years). Among patients who experienced a cognitive effect of Grade 2 or worse, the median time to improvement to Grade 1 or complete resolution was 8.1 weeks.

Cognitive effects include memory impairment, cognitive disorder, confusional state, delirium, and disorientation.



Advise patients and their caregivers of the potential cognitive effects, and the **importance of notifying their healthcare provider** of any new or worsening symptoms. Advise patients not to drive or operate hazardous machinery if they are experiencing cognitive adverse reactions.

ICH=intracranial hemorrhage.

Indication & Important Safety Information

INDICATION

AYVAKIT® (avapritinib) is indicated for the treatment of adult patients with advanced SM (AdvSM) including patients with aggressive systemic mastocytosis (ASM), systemic mastocytosis with an associated hematological neoplasm (SM-AHN), and mast cell leukemia (MCL).

Limitations of Use: AYVAKIT is not recommended for the treatment of patients with AdvSM with platelet counts of $<50 \times 10^9/L$.

IMPORTANT SAFETY INFORMATION

Intracranial Hemorrhage—Serious intracranial hemorrhage (ICH) may occur with AYVAKIT treatment; fatal events occurred in $<1\%$ of patients. Overall, ICH (e.g., subdural hematoma, ICH, and cerebral hemorrhage) occurred in 2.9% of 749 patients who received AYVAKIT in clinical trials. In AdvSM patients who received AYVAKIT at 200 mg daily, ICH occurred in 2 of 75 patients (2.7%) who had platelet counts $\geq 50 \times 10^9/L$ prior to initiation of therapy and in 3 of 80 patients (3.8%) regardless of platelet counts.

Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH. Permanently discontinue AYVAKIT if ICH of any grade occurs.

A platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in AdvSM patients with platelet counts $<50 \times 10^9/L$. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of $<50 \times 10^9/L$ by treatment interruption or dose reduction.

Cognitive Effects—Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 33% of 995 patients overall in patients who received AYVAKIT in clinical trials including 28% of 148 AdvSM patients (3% were Grade ≥ 3). Depending on the severity and indication, withhold AYVAKIT and then resume at same dose or at a reduced dose upon improvement, or permanently discontinue.

Photosensitivity—AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials ($n=1049$), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment.

Embryo-Fetal Toxicity—AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective contraception during treatment with AYVAKIT and for 6 weeks after the final dose of AYVAKIT. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks following the final dose.

Adverse Reactions—The most common adverse reactions ($\geq 20\%$) were edema, diarrhea, nausea, and fatigue/asthenia.

Drug Interactions—Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors. If coadministration with a moderate CYP3A inhibitor cannot be avoided, reduce dose of AYVAKIT. Avoid coadministration of AYVAKIT with strong or moderate CYP3A inducers. If contraception requires estrogen, limit ethinyl estradiol to ≤ 20 mcg unless a higher dose is necessary.

To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

AYVAKIT is available in 25-mg, 50-mg, 100-mg, and 200-mg tablets.

Please click here to see the full [Prescribing Information for AYVAKIT](#).

The ONLY selective targeted therapy for Advanced SM designed for potent inhibition of KIT D816V¹



Advanced SM is driven by the KIT D816V mutation in ~95% of cases.^{6,11,12}



Proven efficacy across all Advanced SM subtypes and regardless of prior antineoplastic therapy.^{1,24}



One tablet, once-daily dosing starting at 200 mg.¹



Generally well tolerated with specific guidelines for patient monitoring and management; most common adverse reactions were Grade 1 or 2.¹

SELECT SAFETY INFORMATION

Intracranial Hemorrhage (cont'd)—Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia. Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH. Permanently discontinue AYVAKIT if ICH of any grade occurs.

A platelet count must be performed prior to initiating therapy. AYVAKIT is not recommended in AdvSM patients with platelet counts $<50 \times 10^9/L$. Following treatment initiation, platelet counts must be performed every 2 weeks for the first 8 weeks. After 8 weeks of treatment, monitor platelet counts every 2 weeks or as clinically indicated based on platelet counts. Manage platelet counts of $<50 \times 10^9/L$ by treatment interruption or dose reduction.

Please see Important Safety Information on pages 16-17 and the full [Prescribing Information](#) for AYVAKIT.

Enroll your patients at time of prescription to support the patient experience and access to programs

YourBlueprint[®] provides dedicated, personalized support to help eligible patients from **Day 1**.

Blueprint Medicines offers a series of programs to support patient access, including:

- Co-pay Support
- Patient Assistance Program
- QuickStart
- Prior Authorization Support
- Coverage Interruption



To see how we can help:

- ☎ Call **1-888-BLUPRNT (1-888-258-7768)** Monday-Friday, 8 AM-8 PM ET
- Visit www.YourBlueprint.com/HCP

References: 1. AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; November 2024. 2. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines[®]) for Systemic Mastocytosis V.3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed June 14, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 3. Theoharides TC et al. *N Engl J Med*. 2015;373(2):163-172. 4. Jennings SV et al. *Immunol Allergy Clin North Am*. 2018;38(3):505-525. 5. Lim KH et al. *Blood*. 2009;113(23):5727-5736. 6. Verstovsek S. *Eur J Haematol*. 2013;90(2):89-98. 7. Gotlib J et al. *Blood*. 2013;121(13):2393-2401. 8. Gülen T et al. *J Intern Med*. 2016;279(3):211-228. 9. Sperr WR et al. *Lancet Haematol*. 2019;6(12):e638-e649. 10. Schwaab J et al. *J Allergy Clin Immunol Pract*. 2020;8(9):3121-3127. 11. Gilreath JA et al. *Clin Pharmacol*. 2019;11:77-92. 12. Garcia-Montero AC et al. *Blood*. 2006;108(7):2366-2372. 13. Valent P et al. *Blood*. 2017;129(11):1420-1427. 14. da Silva EZM et al. *J Histochem Cytochem*. 2014;62(10):698-738. 15. Evans EK et al. *Sci Transl Med*. 2017;9(414):eaa01690. 16. WHO Classification of Tumours Editorial Board. Haematolymphoid tumours [Internet]. Lyon (France): International Agency for Research on Cancer; 2024 [cited April 24, 2024]. (WHO Classification of Tumours Series, 5th ed.; vol. 11). Available from: <https://tumourclassification.iarc.who.int/chapters/63> 17. Craig JW et al. *Mod Pathol*. 2020;133(6):1135-1145. 18. Reiter A et al. *Blood*. 2020;135(16):1365-1376. 19. Arock M et al. *Leukemia*. 2015;29(6):1223-1232. 20. Shomali W, Gotlib J. *Hematology*. 2018;2018(1):127-136. 21. EXPLORER Study. ClinicalTrials.gov. NCT02561988. Accessed February 17, 2023. 22. PATHFINDER Study. ClinicalTrials.gov. NCT03580655. Accessed February 17, 2023. 23. Shomali W, Gotlib J. *Int J Mol Sci*. 2021;22(6):2983. 24. Data on file. Blueprint Medicines Corporation, Cambridge, MA. 2021.

